⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked stocksUnlock stocks

Novo slumps, Lilly gains on trial data results

Published 20/12/2024, 12:52
© Reuters.

© Reuters.

LLY
0.50%
NVO
0.15%

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) plummeted over 19% in premarket trading Friday after the results from its phase 3 trial of CagriSema, its next-generation obesity drug, disappointed.

Meanwhile, rival Eli Lilly (NYSE:LLY) surged more than 9%.

Novo Nordisk’s REDEFINE 1 trial showed that people treated with CagriSema, a combination of cagrilintide and semaglutide, achieved a weight loss of 22.7% after 68 weeks.

While statistically significant and superior to the results achieved with either drug alone, the weight loss fell short of the target of 25%.

"This was achieved even though only 57% of patients reached the highest CagriSema dose," commented Martin Holst Lange, Novo Nordisk’s executive vice president for Development.

Lange highlighted the drug’s potential, noting the company’s plans to "further explore the additional weight loss potential of CagriSema."

The trial involved 3,417 overweight or obese participants and evaluated the efficacy and safety of CagriSema. The trial achieved its primary endpoint by "demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo."

While the results showed promise, the market reacted negatively to the below-expectation outcomes.

Conversely, the sharp rise in Eli Lilly’s stock reflects growing confidence in its competing obesity treatments.

The results from Novo’s second phase 3 trial, REDEFINE 2, in adults with type 2 diabetes and either obesity or overweight are expected during the first half of 2025.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

LLY: A Bull or Bear Market Play?

Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year..

In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record.

With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies.

So if LLY is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Unlock ProPicks now

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.